Back to top
more

Edwards Lifesciences (EW)

(Real Time Quote from BATS)

$66.86 USD

66.86
2,517,162

+0.63 (0.95%)

Updated Nov 11, 2024 12:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 250)

Industry: Medical - Instruments

Zacks News

Edwards Lifesciences' (EW) THVT Likely to Drive Q4 Earnings

Edwards Lifesciences (EW) is expected to gain from strength in THVT on continued therapy adoption across all geographies.

    Edwards Lifesciences Buys Harpoon Medical, Expands Portfolio

    Edwards Lifesciences (EW) expands Surgical Heart Valve Therapy segment with the buyout of Harpoon Medical.

      Implied Volatility Surging for Edwards Lifesciences (EW) Stock Options

      Edwards Lifesciences (EW) needs investors to pay close attention to the stock based on moves in the options market lately.

        EW vs. BCR: Which Stock is Poised for Better Q3 Earnings?

        Political turmoil and the health policy related battle apart, majority of the MedTech stocks' bottom line is likely to be hurt in the third quarter on escalating costs induced by consecutive hurricanes and Mexico earthquakes.

          Will Edwards Lifesciences (EW) Gain on THVT in Q3 Earnings?

          Edwards Lifesciences (EW) will likely ride high in Q3 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve Therapy space.

            Edwards Lifesciences, Bed Bath & Beyond, Annaly Capital Management, AGNC Investment and ARMOUR Residential REIT highlighted as Zacks Bull and Bear of the Day

            Edwards Lifesciences, Bed Bath & Beyond, Annaly Capital Management, AGNC Investment and ARMOUR Residential REIT highlighted as Zacks Bull and Bear of the Day

              Align Technology (ALGN) Prospects Bright, Competition Rife

              Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.

                Kevin Cook headshot

                Bull of the Day: Edwards Lifesciences (EW)

                The #1 non-surgical heart valve replacement technology owes its roots to a hydraulic pump engineer named Miles Edwards

                  Medtronic Advances in Pain Therapy With U.S. Intellis Launch

                  We look forward to a solid customer adoption of Medtronic's (MDT) Intellis platform, considering the vast and expanding market for chronic pain management.

                    Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

                    The market is upbeat about Abbott (ABT) acquiring the national reimbursement for FreeStyleLibre glucose monitoring system in the United Kingdom. Several product launches also add value.

                      Amedisys or Chemed: Which is a Better Investment Choice?

                      After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).

                        Why Should Investors Add Amedisys (AMED) to Their Portfolio?

                        Amedisys (AMED) rides high on solid prospects with new opportunities within home health and hospice services segments.

                          Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

                          IDEXX Laboratories (IDXX) continues to boost investor's confidence with strong companion animal business along with balanced growth across all segments.

                            Why is Edwards Lifesciences (EW) a Strong Buy Stock Now?

                            Several recent FDA product-approvals boost investors' trust in Edwards Lifesciences' (EW) stock.

                              Here's Why You Should Add Chemed (CHE) to Your Portfolio

                              Chemed (CHE) bolsters investor's confidence with continued strength in Roto-Rooter business.

                                Here's Why You Should Bet on BioTelemetry (BEAT) Stock Now

                                BioTelemetry's (BEAT) consistent efforts in product innovation through research and development buoy optimism. Also, the recent acquisition instills confidence in investors.

                                  Becton, Dickinson Ultra-Fine Needle to Improve Diabetic Care

                                  Becton, Dickinson and Company's (BDX) latest micro pen needle will enhance the scope of its Diabetic Care unit.

                                    Neogen (NEOG) Earnings and Revenues Beat Estimates in Q1

                                    Neogen (NEOG) rides high on balanced growth across all business segments.

                                      Halyard Health (HYH) Announces Positive Data on COOLIEF

                                      Halyard Health's (HYH) positive clinical data on COOLIEF will boost fortunes in the chronic pain space.

                                        Surmodics Receives FDA's Approval for PTA Balloon Catheter

                                        Surmodics (SRDX) receives FDA's approval for PTA Balloon Catheter, which will boost its presence in the global peripheral artery disease market.

                                          Will Hurricanes Choke Cardiovascular (CSII) Q1 Performance?

                                          Cardiovascular (CSII) expects Q1 revenues to be affected by the Harvey and Irma hurricanes. However, the long-term growth prospects are unlikely to be affected.

                                            Myriad Genetics Presents Favorable riskScore Test Data

                                            Myriad (MYGN) presenting positive riskScore data at the NSGC conference in Columbus, OH buoys optimism. Notably, with riskScore the company intends to boost its myRisk Hereditary Cancer test suite.

                                              McKesson to Gain From Distribution Business Amid Pricing Woes

                                              McKesson Corporation's (MCK) Distribution business driven by market growth and acquisitions is expected to aid growth. However, pricing remains a concern.

                                                Surmodics Presents Encouraging SurVeil DCB Data at VIVA Meet

                                                Surmodics' (SRDX) promising data on SurVeil DCB will boost its fortunes in the symptomatic peripheral artery disease space.

                                                  Inovalon Holdings' ONE Platform Chosen by UnitedHealthcare

                                                  Inovalon Holding (INOV) will be able to expand in the population health management space through the selection of its proprietary ONE Platform by UnitedHealthcare.